risperidone has been researched along with Daytime Sleepiness in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 9.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 6.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 5.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "Risperidone was well tolerated, and patients treated with risperidone demonstrated significantly greater improvement at endpoint on the ABC than those who received placebo [-27." | 2.71 | Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. ( Eerdekens, M; Gagiano, C; Read, S; Thorpe, L; Van Hove, I, 2005) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 2.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kram, BL | 1 |
| Kram, SJ | 1 |
| Brooks, KR | 1 |
| Chang, KD | 1 |
| Findling, RL | 1 |
| McDougle, CJ | 2 |
| Stigler, KA | 1 |
| Erickson, CA | 1 |
| Posey, DJ | 2 |
| Gagiano, C | 1 |
| Read, S | 1 |
| Thorpe, L | 1 |
| Eerdekens, M | 1 |
| Van Hove, I | 1 |
| Aman, MG | 1 |
| Arnold, LE | 1 |
| Vitiello, B | 1 |
| Scahill, L | 1 |
| Davies, M | 1 |
| McCracken, JT | 1 |
| Tierney, E | 1 |
| Nash, PL | 1 |
| Chuang, S | 1 |
| Martin, A | 1 |
| Shah, B | 1 |
| Gonzalez, NM | 1 |
| Swiezy, NB | 1 |
| Ritz, L | 1 |
| Koenig, K | 1 |
| McGough, J | 1 |
| Ghuman, JK | 1 |
| Lindsay, RL | 1 |
| Zhong, KX | 1 |
| Sweitzer, DE | 1 |
| Hamer, RM | 1 |
| Lieberman, JA | 1 |
| Kopecek, M | 1 |
| Mohr, P | 1 |
| Novak, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms[NCT00005014] | Phase 3 | 101 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for risperidone and Daytime Sleepiness
| Article | Year |
|---|---|
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil | 2008 |
3 trials available for risperidone and Daytime Sleepiness
| Article | Year |
|---|---|
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.
Topics: Adolescent; Adult; Attention Deficit and Disruptive Behavior Disorders; Disorders of Excessive Somno | 2005 |
Acute and long-term safety and tolerability of risperidone in children with autism.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Autistic Disorder; Body M | 2005 |
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Dibenzothiazepines; Disord | 2006 |
2 other studies available for risperidone and Daytime Sleepiness
| Article | Year |
|---|---|
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzo | 2015 |
Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions.
Topics: Antipsychotic Agents; Anxiety Disorders; Disorders of Excessive Somnolence; Dose-Response Relationsh | 2006 |